Clinical Trials Directory

Trials / Sponsors / Hrain Biotechnology Co., Ltd.

Hrain Biotechnology Co., Ltd.

Industry · 13 registered clinical trials — 5 currently recruiting.

StatusTrialPhaseStarted
RecruitingTo Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or
Multiple Myeloma, Plasma Cell Leukemia
EARLY_Phase 12023-07-04
UnknownTo Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-
B-cell Acute Lymphoblastic Leukemia
EARLY_Phase 12022-10-21
RecruitingHuman CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Pa
Central Nervous System Lymphoma
EARLY_Phase 12022-08-12
RecruitingHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Multiple Myeloma
Phase 22022-07-12
UnknownTo Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-
Acute Lymphoblastic Leukemia
Phase 12022-02-10
Active Not RecruitingTo Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Multiple Myeloma
EARLY_Phase 12022-02-09
RecruitingEvaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with
Acute Myeloid Leukemia (AML)
EARLY_Phase 12022-01-26
RecruitingHuman CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lym
B-cell Non-Hodgkin's Lymphoma
Phase 22021-08-09
UnknownBCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
EARLY_Phase 12019-07-08
UnknownHuman BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Phase 12019-07-01
UnknownHuman CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
CD19-positive, Acute Lymphoblastic Leukemia
Phase 12019-03-13
UnknownAnti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
POMES Syndrome, Relapsed and Refractory POMES Syndrome
Phase 12019-02-27
UnknownHuman CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
CD19-positive, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Phase 12018-11-13